Biotech Startups

XenImmune is an immuno-oncology company developing first-in-class molecules that apply the biology of organ transplant hyperacute rejection to fight cancer by "painting" tumors with foreign blood groups to trigger anti-tumor immune responses. Its lead therapy has shown proof of concept in common tumor types in in vitro and in vivo settings.

1 investor

Xenter develops wireless medical technologies and a medical intelligence platform that aggregates devices, medical data, and diagnostics to apply AI in medicine, with expertise in medical devices and interventional cardiology. The company operates from Salt Lake City with a global network.

1 investor

1 investor

XGEN Venture is an Italian alternative investment fund manager (SGR) that makes early-stage investments in private life science research and development companies. It focuses on startups developing novel solutions for high unmet medical needs and is investing through its XGEN Venture Life Science fund.

1 investor

Crosslink Therapeutics develops protein engineering and cancer therapies, focusing on immunological and oncology treatments in the biopharmaceutical sector.

1 investor

XM Therapeutics develops extracellular matrix-based therapies to treat patients with chronic disorders, with initial applications targeting heart failure and pulmonary fibrosis. The company is based in Providence, Rhode Island and leverages partnerships with Brown University for research and development.

1 investor

1 investor

XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding. It serves biotech companies seeking capital to advance their internal drug candidates, holding a portfolio of 120+ assets.

1 investor

A biotechnology company developing a peptide-based delivery platform that uses lipid raft targeting to transport therapeutic proteins into the cytosol of human cells with minimal lysosomal degradation. The technology is designed for pharmaceutical companies and researchers needing intracellular delivery of therapeutic macromolecules.

1 investor

Xpan develops a single universal trocar for minimally invasive surgery (MIS) that accommodates all surgical instruments, aiming to replace traditional trocar access. The device is intended for MIS surgeons and the surgical device market.

1 investor

Xterna develops xeno nucleic acid (XNA) technology to engineer cell-specific binders aimed at treating diseases currently considered untreatable. The company operates in the biotechnology and therapeutics space.

1 investor

1 investor

Xyall operates in medical technology and molecular diagnostics, leveraging expertise in digital pathology and health innovation to scale diagnostic solutions.

1 investor

Xylo develops mechanism-based drug therapies targeting psychiatric and neurological disorders using computational and rational drug design approaches. The company serves patients and healthcare systems seeking novel treatments for complex neuropsychiatric conditions.

1 investor

XYLYX develops transplantation technologies using regenerative medicine, bioengineering, and translational science to expand access to organ transplantation. The company works with surgeons, physicians, and regenerative medicine experts to advance tissue engineering and clinical innovation for transplant applications.

1 investor

Yanyin Tech develops an AI agent platform for biomedical research and drug discovery, offering a suite of tools including bioinformatics and laboratory collaboration software for pharmaceutical companies, research institutions, and universities.

1 investor

Yarok Microbio develops a rapid microbiological testing system for pathogen detection in fresh food products and production environments. The platform enables faster, more reliable testing with minimal training requirements, serving food producers and testing laboratories across the fresh food industry.

1 investor

Yarrow Bioscience develops a first-in-class anti-TSHR antibody to treat thyroid autoimmune diseases, specifically Graves' disease and thyroid eye disease. It operates in the biotech and therapeutics space.

1 investor

YISSUM is a technology transfer organization founded in 1964 that commercializes research from the Hebrew University, connecting groundbreaking academic innovations with industry partners and global markets. It operates an ecosystem supporting researchers, entrepreneurs, and industry collaborators in licensing, partnerships, and venture creation.

1 investor

Ykrita develops the EBDLR System, a bioengineered liver-assist device that supports blood purification and regeneration for patients with acute liver failure, offering an alternative to transplant surgery. The company focuses on innovative medical technologies to improve patient outcomes and make healthcare more accessible and effective.

1 investor

Y-mAbs develops radioimmunotherapy and antibody-based therapies targeting pediatric and adult cancers, with a heritage in high-risk neuroblastoma and expansion into additional oncology indications.

1 investor

YolTech Therapeutics develops in vivo gene editing medicines using a proprietary lipid nanoparticle delivery platform to treat genetic, metabolic, and autoimmune diseases. The company operates clinical-stage programs targeting conditions including Transthyretin Amyloidosis, Alpha-1 Antitrypsin Deficiency, Primary Hyperoxaluria, Beta Thalassemia/Sickle Cell Disease, and Familial Hypercholesterolemia.

1 investor

Yosemite is working toward making cancer non-lethal, focusing on cancer research and treatment.

1 investor

Yseop provides an AI-powered platform that automates medical writing and regulatory reporting tasks for life sciences teams, accelerating document submission timelines within the CTD pyramid framework. The platform uses neuro-symbolic AI to transform complex documentation workflows and ensure compliance in pharmaceutical regulatory processes.

1 investor